| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/22/2009 | WO2008110339A3 Polymorphs of rivastigmine hydrogentartrate |
| 01/22/2009 | WO2008076447A3 Treatments of therapy-resistant diseases comprising drug combinations |
| 01/22/2009 | US20090023808 Production and Purification of Esters of Polyunsaturated Fatty Acids |
| 01/22/2009 | US20090023807 Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters |
| 01/22/2009 | US20090023802 liquid-crystal media used in electro-optical displays; treatment or prophylaxis of diseases or symptoms which can be influenced by inhibition of cannabinoid receptors |
| 01/22/2009 | US20090023800 Cannabinoid receptor modulator |
| 01/22/2009 | US20090023799 CRYSTALS OF (2-AMINO-4,5,6,7-TETRAHYDROBENZO[b]THIEN-3-YL)(4-CHLOROPHENYL)METHANONE |
| 01/22/2009 | US20090023795 Kinase Inhibitors And Methods Of Use Thereof |
| 01/22/2009 | US20090023794 Use of Sumoylation Inhibitors for the Treatment of Neurodegenerative Disease |
| 01/22/2009 | US20090023791 PH-dependent NMDA receptor antagonists |
| 01/22/2009 | US20090023789 N-[(5Z)-4-butyl-2-tert-butylisothiazol-5(2H)-ylidene]-5-chloro-2-methoxybenzamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants |
| 01/22/2009 | US20090023785 6-substituted nicotinamide derivatives as opioid receptor antagonists |
| 01/22/2009 | US20090023780 Therapeutic use of a derivative of thienylcyclohexylamine |
| 01/22/2009 | US20090023774 Pyridine analogs as C5A antagonists |
| 01/22/2009 | US20090023773 Compositions and methods for modulating gated ion channels |
| 01/22/2009 | US20090023772 Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors |
| 01/22/2009 | US20090023770 1-methoxy-2-methyl-3-[(4-nitrophenyl)sulphonyl]indolizine, used as angiogenesis inhibitors |
| 01/22/2009 | US20090023765 Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
| 01/22/2009 | US20090023762 Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies |
| 01/22/2009 | US20090023756 Substituted quinazolines as pde10 inhibitors |
| 01/22/2009 | US20090023755 Use of istradefylline for treating behavioral disorders |
| 01/22/2009 | US20090023750 Novel salts of piperazine compounds as d3/d2 antagonists |
| 01/22/2009 | US20090023749 Crystal structure; antidepressants; anxiolytic agents; eating disorders; bipolar disorders; Alzheimer's disease; sleep disorders; psychiatric disorders; sexual dysfunctions; fibromyalgia |
| 01/22/2009 | US20090023744 Combination therapy for depression |
| 01/22/2009 | US20090023742 Thiazolones for use as pi3 kinase inhibitors |
| 01/22/2009 | US20090023739 Capase inhibitors and uses thereof |
| 01/22/2009 | US20090023737 Imidazo-Pyridazines, Triazolo-Pyridazines and Related Benzodiazepine Receptor Ligands |
| 01/22/2009 | US20090023732 Citrate Salt of an Indole Derivative and its Pharmaceutical Use |
| 01/22/2009 | US20090023728 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof |
| 01/22/2009 | US20090023723 Purinone derivatives for treating neurodegenerative diseases |
| 01/22/2009 | US20090023722 Amide substituted imidazoquinolines |
| 01/22/2009 | US20090023721 Novel Substituted Tetracyclic Tetrahydrofuran, Pyrrolidine and Tetrahydrothiophene Derivatives and Their Use as a Medicament |
| 01/22/2009 | US20090023717 Morphine-bridged indazole derivatives |
| 01/22/2009 | US20090023712 Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin |
| 01/22/2009 | US20090023707 1-{4-[4-(pyrrolidin-1-ylmethyl)-1,3-oxazol-2-yl]benzyl}-1H-benzimidazole, used for the treatment of central nervous system disorders |
| 01/22/2009 | US20090023705 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders |
| 01/22/2009 | US20090023700 Neuroprotective treatments |
| 01/22/2009 | US20090023697 Analgesia method |
| 01/22/2009 | US20090023691 Delaying the ageing process and disorders caused by ageing |
| 01/22/2009 | US20090023676 RNA Interference Mediated Inhibition of MAP Kinase Gene Expression or Expression of Genes Involved in MAP Kinase Pathway Using Short Interfering Nucleic Acid (SiNA) |
| 01/22/2009 | US20090023675 RNA Interference Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid (siNA) |
| 01/22/2009 | US20090023674 snRNA gene-like transcriptional units and uses thereof |
| 01/22/2009 | US20090023659 Using cell surface adhesion proteins specific immunoglobulin to target therapeutics to tumorous; immunodiagnostics; immunotherapy |
| 01/22/2009 | US20090023657 Catecholamine regulated protein |
| 01/22/2009 | US20090023627 Compositions and methods for alzheimer's disease |
| 01/22/2009 | US20090023145 Methods of diagnosing or prognosing Alzheimer's disease |
| 01/22/2009 | US20090022825 Method for Predicting Whether Subjects With Mild Cognitive Impairment (MCI) Will Develop Alzheimer's Disease |
| 01/22/2009 | US20090022823 Methods for Administering Active Agents to CYP3A4 Sensitive Patients |
| 01/22/2009 | US20090022799 Compositions that contain beta-glucan to be used for the prevention and treatment of disease and methods for their use |
| 01/22/2009 | US20090022798 Formulations of nonopioid and confined opioid analgesics |
| 01/22/2009 | US20090022789 Enhanced formulations of lamotrigine |
| 01/22/2009 | US20090022733 Methods for treating Disease with an IL-1R antibody |
| 01/22/2009 | US20090022732 Crystal of a cytochrome-ligand complex and methods of use |
| 01/22/2009 | US20090022724 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 01/22/2009 | US20090022712 Compositions and Methods for Inhibiting Leukocyte Function |
| 01/22/2009 | US20090022711 Methods of modulating cell death based on the bit-1/aes regulatory pathway |
| 01/22/2009 | US20090022701 Administering to the patient an amount of CLN2 protein (Neuronal ceroid lipofuscinoses (NCLs)) effective to reduce or eliminate the symptoms caused by the deficiencyl in CLN2 protein; Central nervous system disorders |
| 01/22/2009 | US20090022694 Sirt1 inhibition |
| 01/22/2009 | US20090022670 Novel compounds |
| 01/22/2009 | US20090022667 METHODS OF TREATING COGNITIVE DISORDERS BY INHIBITION OF Gpr12 |
| 01/22/2009 | CA2700477A1 Method for reducing intracranial pressure |
| 01/22/2009 | CA2696833A1 Disease treatment via antimicrobial peptides or their inhibitors |
| 01/22/2009 | CA2694748A1 Sodium channel inhibitors |
| 01/22/2009 | CA2693959A1 Inhibitors of beta amyloid production |
| 01/22/2009 | CA2693588A1 Sodium channel inhibitors |
| 01/22/2009 | CA2693369A1 Methods for treating anxiety |
| 01/22/2009 | CA2693141A1 Use of a granulin or a granulin-like compound for the therapy or prophylaxis of chronic pain |
| 01/22/2009 | CA2693138A1 Aminoalkylazole derivatives as histamine-3 antagonists |
| 01/22/2009 | CA2693110A1 Methods for promoting wakefulness |
| 01/22/2009 | CA2690110A1 Ampa receptor antagonists for neuropathic pain |
| 01/22/2009 | CA2690087A1 Ampa receptor antagonists and zonisamide for neuropathic pain |
| 01/22/2009 | CA2690086A1 Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain |
| 01/21/2009 | EP2017289A1 Pharmaceutical composition for conformational disease |
| 01/21/2009 | EP2017275A1 Benzisoxazole compound |
| 01/21/2009 | EP2016948A2 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 01/21/2009 | EP2016943A1 Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments |
| 01/21/2009 | EP2016941A1 Transdermally absorbable donepezil preparation |
| 01/21/2009 | EP2016939A1 Transdermally absorbable preparation comprising anti-dementia agent |
| 01/21/2009 | EP2016061A1 Compounds which potentiate ampa receptor and uses thereof in medicine |
| 01/21/2009 | EP2016039A1 Terphenyl derivatives for treatment of alzheimer' s disease |
| 01/21/2009 | EP2015769A2 Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof |
| 01/21/2009 | EP2015766A1 Cyclised alpha-conotoxin peptides |
| 01/21/2009 | EP2015765A2 Methods amd compositions for treating conditions |
| 01/21/2009 | EP2015764A2 Aqueous tobacco leaf extract, uses thereof in the treatment of dependence |
| 01/21/2009 | EP2015751A2 Salts of pyridazine compounds |
| 01/21/2009 | EP2015750A2 Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| 01/21/2009 | EP2015749A2 Methods for treating cognitive and other disorders |
| 01/21/2009 | EP2015747A2 Use of n-aminoimidazole cytoprotective compounds for treating cell death and/or gsk-3 mediated diseases |
| 01/21/2009 | EP2015741A2 Histone deacetylase inhibitors for the treatment of neurodegeneration |
| 01/21/2009 | EP2015739A1 Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions |
| 01/21/2009 | EP1846410B1 Dihydroquinazolinones as 5ht modulators |
| 01/21/2009 | EP1791904A4 Method of treating organophosphorous poisoning |
| 01/21/2009 | EP1663983B1 N-substituted, 6,8-dialkoxy-1,2,3,4-tetrahydro-1h-isoquinoline as potassium channels modulators |
| 01/21/2009 | EP1570052B1 Method for culturing neural stem cells using hepatocyte growth factor |
| 01/21/2009 | EP1549619B1 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
| 01/21/2009 | EP1531816B1 Spirocyclic piperidines as mch1 antagonists and uses thereof |
| 01/21/2009 | EP1506228B1 Role of p62 in aging-related disease |
| 01/21/2009 | EP1499610B1 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them |
| 01/21/2009 | EP1353691B1 Molecular antigen array presenting amyloid beta |
| 01/21/2009 | EP1343495B1 Methods of treating anxiety disorders |